Literature DB >> 34676031

Sulfonylamide Compounds as CDK2 Inhibitors for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 34676031      PMCID： PMC8521608          DOI： 10.1021/acsmedchemlett.1c00471

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Small molecule modulators targeting protein kinase CK1 and CK2.

Authors:  Yuting Qiao; Tingkai Chen; Hongyu Yang; Yao Chen; Hongzhi Lin; Wei Qu; Feng Feng; Wenyuan Liu; Qinglong Guo; Zongliang Liu; Haopeng Sun
Journal:  Eur J Med Chem       Date:  2019-08-01       Impact factor: 6.514

Review 2.  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).

Authors:  Concepción Sánchez-Martínez; María José Lallena; Sonia Gutiérrez Sanfeliciano; Alfonso de Dios
Journal:  Bioorg Med Chem Lett       Date:  2019-08-26       Impact factor: 2.823

Review 3.  A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.

Authors:  Brilliant N Marak; Jayanta Dowarah; Laldingluaia Khiangte; Ved Prakash Singh
Journal:  Eur J Med Chem       Date:  2020-07-15       Impact factor: 6.514

4.  Application of Machine Learning Techniques to Predict Binding Affinity for Drug Targets: A Study of Cyclin-Dependent Kinase 2.

Authors:  Gabriela Bitencourt-Ferreira; Amauri Duarte da Silva; Walter Filgueira de Azevedo
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

Review 5.  Pyrazolopyrimidines as anticancer agents: A review on structural and target-based approaches.

Authors:  Vivek Asati; Arjun Anant; Preeti Patel; Kamalpreet Kaur; G D Gupta
Journal:  Eur J Med Chem       Date:  2021-08-18       Impact factor: 6.514
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.